A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, PK and the Effect of MK-8189 on QTc in Participants With Schizophrenia
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 3
- 主要终点
- Number of Participants Experiencing an Adverse Event (AE)
研究概览
简要总结
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of MK-8189 in participants with schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
Double-blind
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Meets diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria with the onset of the first episode being no less than 2 years prior to screening and monotherapy with antipsychotics for treatment should be indicated.
- •Is in the non-acute phase of their illness and clinically stable for 3 months prior to screening as demonstrated by: 1) no clinically significant change in dose of prescribed antipsychotic medication, or clinically significant change in antipsychotic medication to treat symptoms of schizophrenia for two months prior to screening; 2) no increase in level of psychiatric care due to worsening of symptoms of schizophrenia for three months prior to screening.
- •Has a history of receiving and tolerating antipsychotic medication within the usual dose range employed for schizophrenia.
- •Is able to discontinue the use of all antipsychotic medication at least 5 days or 3 half-lives (whichever is longer) prior to Day -1 and during the study period.
排除标准
- •Is at imminent risk of self-harm.
- •Has a history of cancer (malignancy). Exceptions: 1) adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix; 2) malignancies which have been successfully treated ≥10 years prior to the prestudy (screening) visit; 3) highly unlikely to sustain a recurrence for the duration of the study.
- •Has evidence or history of a primary DSM-5 axis I psychiatric diagnosis other than schizophrenia or schizoaffective disorder per the allowed DSM-5 criteria within one month of screening.
- •Has evidence or history of mental retardation, borderline personality disorder, anxiety disorder, or organic brain syndrome.
- •Has a history of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia.
- •Has a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
- •Has a DSM-5 defined substance use disorder (excluding nicotine and caffeine) within 3 months of screening.
- •Has a history of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures.
- •Has a clinically significant history or presence of sick sinus syndrome, first, second, or third degree atrioventricular (AV) block, myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged corrected QT (QTc) interval, or conduction abnormalities.
- •Meets any of the following cardiac parameters: a history of risk factors for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT syndrome), uncorrected hypokalemia or hypomagnesemia, or is taking concomitant medications that prolong the QT/QTc interval.
- •Has history of repeated or frequent syncope, vasovagal episodes, or epileptic seizures.
- •Has a family history of cardiac sudden death.
- •Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
- •Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
- •Has received or is currently receiving treatment with clozapine for schizophrenia for any length of time or treatment with monoamine oxidase inhibitors within 3 months of screening or cariprazine within 2 months of screening.
- •Has received a parenteral depot antipsychotic medication within 3 months of screening.
- •Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention.
研究组 & 干预措施
MK-8189 Panel A
Participants will receive MK-8189 starting at 48 mg on Day 1 and 60 mg on Day 2.
干预措施: MK-8189 (Drug)
MK-8189 Panel A-1
Participants will receive MK-8189 48 mg on Day 1 and 80 mg on Day 2.
干预措施: MK-8189 (Drug)
MK-8189 Panel C
Participants will receive MK-8189 48 mg on Days 1-2 and 80 mg on Day 3 based on safety and tolerability.
干预措施: MK-8189 (Drug)
Placebo
Participants will receive MK-8189-matching placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants Experiencing an Adverse Event (AE)
时间窗: Up to approximately 17 days
An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs were reported.
Number of Participants Who Discontinue From Study Treatment Due to an AE
时间窗: Up to approximately 3 days
An AE is any untoward medical occurrence in a clinical study participant, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study due to an AE were reported.
次要结局
未报告次要终点